SWOG Cancer Research Network: Lung Neoplasms trials

The registry lists 58 Lung Neoplasms studies with SWOG Cancer Research Network as lead sponsor. 4 are open to participants now and 25 have results posted.

Phase 1 3Phase 2 41Phase 3 12No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted
• Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerActive, not recruitingNCT03939481Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• Lung-MAP S1400K: c-MET PositiveCompletedNCT03574753Phase 2Results posted
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT03377556Phase 2Results posted
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results posted
• Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02965378Phase 2/3Results posted
• Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesTerminatedNCT02926638Phase 2/3Results posted
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results posted
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesCompletedNCT02785913Phase 2Results posted
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersCompletedNCT02766335Phase 2/3Results posted
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)CompletedNCT02728596Not applicableResults posted
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results posted
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedNCT02134912Phase 2Results posted
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerTerminatedNCT00946712Phase 3Results posted
• S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung CancerCompletedNCT00792701Phase 2Results posted
• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00770120Phase 2Results posted
• S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00661193Phase 2Results posted
• S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung CancerCompletedNCT00445848Phase 2Results posted
• S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar CarcinomaCompletedNCT00436332Phase 2Results posted
• S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerTerminatedNCT00288054Phase 1Results posted
• S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTerminatedNCT00265785Phase 2Results posted
• S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast TumorsCompletedNCT00062439Phase 2Results posted
• S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung CancerCompletedNCT00045162Phase 3Results posted
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT04625647Phase 2
• Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)Active, not recruitingNCT04268550Phase 2
• Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)WithdrawnNCT04267913Phase 2
• S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib HydrochlorideCompletedNCT01416688
• S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid TumorsWithdrawnNCT00937417Phase 1
• S9925: Collecting and Storing Samples From Patients With Lung CancerCompletedNCT00920010
• S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone MetastasesCompletedNCT00874211
• S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerCompletedNCT00450281
• S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung CancerTerminatedNCT00090961Not applicable
• S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00085501Phase 2
• S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung CancerTerminatedNCT00074295Phase 2
• Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyCompletedNCT00068289Phase 2
• S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung CancerTerminatedNCT00045617Phase 2
• S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone SurgeryTerminatedNCT00032084Phase 3
• S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00030433Phase 2
• S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00026156Phase 2
• S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung CancerTerminatedNCT00014196Phase 2
• S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung CancerCompletedNCT00006487Phase 1
• Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00006484Phase 3
• S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT00004137Phase 2
• S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT00004011Phase 3
• S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by SurgeryCompletedNCT00003723Phase 2
• S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00003587Phase 2
• S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00003158Phase 2
• S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00002969Phase 2
• SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00002642Phase 2